BlueWillow Biologics plans to vaccinate its first patients with a next-generation anthrax vaccine candidate this month. The BW-1010 vaccine—developed in partnership with Porton Biopharma Ltd. (PBL)—is designed to outlast the anthrax vaccine currently stockpiled by the federal government . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge